Inhibition of p38 Mitogen-Activated Protein Kinase Augments Progression of Remnant Kidney Model by Activating the ERK Pathway

American Journal of Pathology

Volumn 164, Issue 2, 2004, Pages 477-485

  Ohashi, Ryuji ^a   Nakagawa, Takahiko ^a   Watanabe, Susumu ^a   Kanellis, John ^a   Almirez, Ramona G ^b   Schreiner, George F ^b   Johnson, Richard J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SCIOS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; CYCLINE; DNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; NPC 31169; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; MACROPHAGE; MALE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; NICK END LABELING; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KIDNEY DISEASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 1542319872     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63138-0     Document Type: Article

References (31)

1. Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40
2. Ono K, Han J: The p38 signal transduction pathway: activation and function. Cell Signal 2000, 12:1-13
3. Herlaar E, Brown Z: p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999, 5:439-447
4. Floege J, Grone HJ: Progression of renal failure: what is the role of cytokines? Nephrol Dial Transplant 1995, 10:1575-1586
5. Kluth DC, Rees AJ: New approaches to modify glomerular inflammation. J Nephrol 1999, 12:66-75
6. Klahr S: Mechanisms of progression of chronic renal damage. J Nephrol 1999, 12(Suppl 2):S53-S62
7. Salituro FG, Germann UA, Wilson KP, Bemis GW, Fox T, Su MS: Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr Med Chem 1999, 6:807-823
8. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE: SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol 2000, 279:L895-L902
9. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ: Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002, 50:507-512
10. Feng Y, Schreiner GF, Chakravarty S, Liu DY, Joly AH: Inhibition of the mitogen activated protein kinase, p38 alpha, prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loading. Atherosclerosis 2001, 158:331-338
11. Matsuoka H, Arai T, Mori M, Goya S, Kida H, Morishita H, Fujiwara H, Tachibana I, Osaki T, Hayashi S: A p38 MAPK inhibitor, FR-167653, ameliorates murine bleamycin-induced pulmonary fibrosis. Am J Physiol 2002, 283:L103-L112
12. Furuichi K, Wada T, Iwata Y, Sakai N, Yoshimoto K, Kobayashi Ki K, Mukaida N, Matsushima K, Yokoyama H: Administration of FR167653, a new anti-inflammatory compound, prevents renal ischaemia/reperfusion injury in mice. Nephrol Dial Transplant 2002, 17:399-407
13. Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA, Schreiner GF, Nikolic-Paterson DJ: Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol 2003, 14:338-351
14. Iwata Y, Wada T, Furuichi K, Sakai N, Matsushima K, Yokoyama H, Kobayashi K: p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas(lpr) mice. J Am Soc Nephrol 2003, 14:57-67
15. Taal MW, Zandi-Nejad K, Weening B, Shahsafaei A, Kato S, Lee KW, Ziai F, Jiang T, Brenner BM, MacKenzie HS: Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int 2000, 58:1664-1676
16. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001, 12:1434-1447
17. Ohashi R, Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N: Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrol 2002, 13:1795-1805
18. Hill CS, Treisman R: Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 1995, 80:199-211
19. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331
20. Wang X, Rao J, Studzinski GP: Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D(3)-induced differentiation of human leukemia HL60 cells. Exp Cell Res 2000, 258:425-437
21. Ishii Y, Sakai S, Honma Y: Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induces the differentiation of human myeloid leukemia cells. Leuk Res 2001, 25:813-820
22. New L, Li Y, Ge B, Zhong H, Mansbridge J, Liu K, Han J: SB203580 promotes EGF-stimulated early morphological differentiation in PC12 cell through activating ERK pathway. J Cell Biochem 2001, 83:585-596
23. Hall JP, Davis RJ: Inhibition of the p38 pathway upregulates macrophage JNK and ERK activities, and the ERK, JNK, and p38 MAP kinase pathways are reprogrammed during differentiation of the murine myeloid M1 cell line. J Cell Biochem 2002, 86:1-11
24. Bokemeyer D, Panek D, Kramer HJ, Lindemann M, Kitahara M, Boor P, Kerjaschki D, Trzaskos JM, Floege J, Ostendorf T: In vivo identification of the mitogen-activated protein kinase cascade as a central pathogenic pathway in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2002, 13:1473-1480
25. Masaki T, Foti R, Hill PA, Ikezumi Y, Atkins RC, Nikolic-Paterson DJ: Activation of the ERK pathway precedes tubular proliferation in the obstructed rat kidney. Kidney Int 2003, 63:1256-1264
26. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ: Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 1992, 42:297-309
27. Lee LK, Meyer TW, Pollock AS, Lovett DH: Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 1995, 96:953-964
28. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742
29. Huang XR, Kitching AR, Tipping PG, Holdsworth SR: Interleukin-10 inhibits macrophage-induced glomerular injury. J Am Soc Nephrol 2000, 11:262-269
30. Kitching AR, Katerelos M, Mudge SJ, Tipping PG, Power DA, Holdsworth SR: Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis. Clin Exp Immunol 2002, 128:36-43
31. Koprak S, Staruch MJ, Dumont FJ: A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: dependence on CD28 signaling and preferential inhibition of IL-10 production. Cell Immunol 1999, 192:87-95